ArticleDermatology research and practice2012
Barrier-restoring therapies in atopic dermatitis: current approaches and future perspectives.
Article in Dermatology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- MicroRNAs in atopic dermatitis: A systematic review.Journal of cellular and molecular medicine · 2020Pooled it
- The Role of MicroRNA in the Pathogenesis of Atopic Dermatitis.International journal of molecular sciences · 2025Review
- The Significant Role of Atopic Skin Diathesis in Prurigo Nodularis.Sisli Etfal Hastanesi tip bulteni · 2024Article
- Acne Vulgaris, Atopic Dermatitis and Rosacea: The Role of the Skin Microbiota-A Review.Biomedicines · 2022Review
- Recent insights into the management of treatment-resistant pediatric atopic dermatitis.International journal of women's dermatology · 2022Review
- A double-blinded placebo-controlled evaluation of adipose-derived mesenchymal stem cells in treatment of canine atopic dermatitis.Veterinary research communications · 2022Article
- JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results.Microorganisms · 2020Review
- Filaggrin and atopic march.Biochemia medica · 2019Review
- Treatment-resistant atopic dermatitis: challenges and solutions.Clinical, cosmetic and investigational dermatology · 2019Review
- Nucleophosmin modulates the alleviation of atopic dermatitis caused by the marine-derived compound dihydroaustrasulfone alcohol.Experimental & molecular medicine · 2018Article
- Leveraging Multilayered "Omics" Data for Atopic Dermatitis: A Road Map to Precision Medicine.Frontiers in immunology · 2018Review
- Molecular Modeling of ClonedIndian journal of microbiology · 2017Article
- Current insights into the role of human β-defensins in atopic dermatitis.Clinical and experimental immunology · 2017Review
- The Importance of Magnesium in Clinical Healthcare.Scientifica · 2017Review
- Inhibitory Activity of Yokukansankachimpihange against Nerve Growth Factor-Induced Neurite Growth in Cultured Rat Dorsal Root Ganglion Neurons.Molecules (Basel, Switzerland) · 2015Article
- Harmful Effects of Synthetic Surface-Active Detergents against Atopic Dermatitis.Case reports in dermatological medicine · 2015Article
- Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis.Allergy, asthma & immunology research · 2014Review
- Lipid abnormalities and lipid-based repair strategies in atopic dermatitis.Biochimica et biophysica acta · 2014Review
- Topical corticosteroid application and the structural and functional integrity of the epidermal barrier.The Journal of clinical and aesthetic dermatology · 2013Article
- Skin-protective effects of a zinc oxide-functionalized textile and its relevance for atopic dermatitis.Clinical, cosmetic and investigational dermatology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis is a multifactorial, chronic relapsing, inflammatory disease, characterized by xerosis, eczematous lesions, and pruritus. The latter usually leads to an "itch-scratch" cycle that may compromise the epidermal barrier. Skin barrier abnormalities in atopic dermatitis may result from mutations in the gene encoding for filaggrin, which plays an important role in the formation of cornified cytosol. Barrier abnormalities render the skin more permeable to irritants, allergens, and microorganisms. Treatment of atopic dermatitis must be directed to control the itching, suppress the inflammation, and restore the skin barrier. Emollients, both creams and ointments, improve the barrier function of stratum corneum by providing it with water and lipids. Studies on atopic dermatitis and barrier repair treatment show that adequate lipid replacement therapy reduces the inflammation and restores epidermal function. Efforts directed to develop immunomodulators that interfere with cytokine-induced skin barrier dysfunction, provide a promising strategy for treatment of atopic dermatitis. Moreover, an impressive proliferation of more than 80 clinical studies focusing on topical treatments in atopic dermatitis led to growing expectations for better therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.